drugset
drugset / Trial / NCT00348439

Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

NCT00348439 ↗

Phase 2 Terminated 29 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

Plasmin is expected to create a posterior vitreous detachment. The pharmacological creation of a posterior vitreous detachment may be beneficial in a variety of conditions.

Timeline

Start
2006-04
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Plasmin Protein / enzyme biologic 27 mg Intravitreal

Indications

vitreoretinal degeneration